05/2024

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

05/2024

May 25, 2024, 10:34 | Insight
Jacob Adashek: Excited to be with such a great group of ASCO Featured Voices
Jacob Adashek, Medical oncology fellow at the Sidney Kimmel Comprehensive Cancer Center at the Johns…
May 25, 2024, 10:32 | Insight
Lung Cancer Europe announces the launch of an important new survey
Lung Cancer Europe shared on X: "Lung Cancer Europe is today announcing the launch of…
May 25, 2024, 10:27 | Blog
Huge thanks to Ben Whitehouse, who arranged for Tower 42 London to be lit up this evening with our emblem - Melanoma Focus UK
Melanoma Focus UK shared on X: "Huge thanks to Ben Whitehouse, a melanoma patient, who very…
May 25, 2024, 10:20 | Drugs
An ASCO 24 Educational Session will review accelerated approval of lifileucel in advanced melanoma
ASCO (American Society of Clinical Oncology) shared on X: "Accelerated approval of lifileucel in advanced melanoma…
May 25, 2024, 10:18 | Insight
Jessica Evans is one of the thousands of dedicated palliative care staff we recognise on National Palliative Care Week - Cancer Institute NSW
Tracey O’Brien shared a post by Cancer Institute NSW on LinkedIn, adding: “Our community relies…
May 25, 2024, 10:11 | Insight
Excellent review by Albert Jang and Shilpa Gupta on papillary RCC - Kidney Cancer Journal
Kidney Cancer Journal shared on X: "Just in Kidney Cancer Journal Excellent review by Albert…
May 25, 2024, 10:05 | Insight
Marco Donia: The Role of PD-L1 Assessment in Dual Checkpoint Inhibition for Melanoma
Marco Donia, Clinical Research Associate Professor at the University of Copenhagen, shared on LinkedIn: "The…
May 25, 2024, 10:00 | Cancer Types
Carcinoid Tumor: What patients should know about
Carcinoid cancer, a subtype of neuroendocrine tumors (NETs), is a rare and complex disease that arises from specialized hormone-producing cells found…
May 25, 2024, 09:57 | Societies
Manni Mohyuddin: Six key take-aways regarding the IMROZ trial while we wait for ASCO 24
Manni Mohyuddin shared on X: "The IMROZ trial (Isa-VRd versus VRd for transplant-ineligible myeloma) just…
May 25, 2024, 09:54 | Blog
Gevorg Tamamyan: The best candidate for ESMO Presidency is Giuseppe Curigliano
Gevorg Tamamyan shared on LinkedIn: "Wonderful person, a great physician-scientist and a dear friend Giuseppe…
All: 2435 Posts: 561 - 570
Special Coverage